Rhoen-Klinikum AG

RHK.SW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RHK.SW stands at 796.3M. In comparison, FME.SW has a market cap of 9.7B. Regarding current trading prices, RHK.SW is priced at CHF 26.00, while FME.SW trades at CHF 32.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RHK.SW currently has a P/E ratio of 71.23, whereas FME.SW's P/E ratio is 10.78. In terms of profitability, RHK.SW's ROE is +0.02%, compared to FME.SW's ROE of +0.03%. Regarding short-term risk, RHK.SW and FME.SW have similar daily volatility (0.00).Check FME.SW's competition here

RHK.SW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RHK.SW stands at 796.3M. In comparison, AEVS.SW has a market cap of 1.1B. Regarding current trading prices, RHK.SW is priced at CHF 26.00, while AEVS.SW trades at CHF 13.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RHK.SW currently has a P/E ratio of 71.23, whereas AEVS.SW's P/E ratio is -56.25. In terms of profitability, RHK.SW's ROE is +0.02%, compared to AEVS.SW's ROE of -0.04%. Regarding short-term risk, RHK.SW is less volatile compared to AEVS.SW. This indicates potentially lower risk in terms of short-term price fluctuations for RHK.SW.Check AEVS.SW's competition here